Treatment exposure
| . | CLL2-BIO . | CLL2-BIG . | CLL2-BAG . | Total . |
|---|---|---|---|---|
| Analysis population [patients with del(17p)/TP53 mut] | 21 | 13 | 17 | 51 |
| Debulking | ||||
| Patients with 1-2 cycles bendamustine (%) | 11 (52) | 8 (62) | 8 (47) | 27 (53) |
| Induction | ||||
| Patients with 6 induction cycles with IO, IG, or AG (%) | 21 (100) | 13 (100) | 17 (100) | 51 (100) |
| Early discontinuation at the end/after induction (%) | 2 (10) | 0 | 1 (6) | 3 (6) |
| Maintenance | ||||
| Patients with ≥1 maintenance cycle with IO, IG, or AG (%) | 19 (91) | 13 (100) | 16 (94) | 48 (94) |
| Mean no. of cycles | 6.9 | 4.9 | 3.7 | 5.3 |
| Patients with full 8 maintenance cycles, 24 mo (%) | 13 (68) | 6 (46) | 2 (13) | 21 (44) |
| Early discontinuation of maintenance (%) | ||||
| Due to adverse events | 1 (5) | 1 (8) | 0 | 2 (4) |
| Due to progressive disease | 4 (21) | 1 (8) | 2 (13) | 7 (15) |
| Death | 1 (5) | 0 | 0 | 1 (2) |
| Discontinuation of maintenance due to uMRD (%) | 0 | 5 (39) | 12 (75) | 17 (35) |
| Mean no. (range) of cycles | NA | 2.4 (2-4) | 3.3 (2-6) | 3.0 (2-6) |
| Duration of treatment | ||||
| Mean (range) duration, mo, of | ||||
| All treatment: debulking, induction, maintenance | 25 (5-32) | 23 (13-34) | 18 (4-30) | 22 (4-34) |
| Targeted treatment: induction and maintenance | 24 (5-31) | 22 (12-32) | 17 (4-30) | 21 (4-32) |
| . | CLL2-BIO . | CLL2-BIG . | CLL2-BAG . | Total . |
|---|---|---|---|---|
| Analysis population [patients with del(17p)/TP53 mut] | 21 | 13 | 17 | 51 |
| Debulking | ||||
| Patients with 1-2 cycles bendamustine (%) | 11 (52) | 8 (62) | 8 (47) | 27 (53) |
| Induction | ||||
| Patients with 6 induction cycles with IO, IG, or AG (%) | 21 (100) | 13 (100) | 17 (100) | 51 (100) |
| Early discontinuation at the end/after induction (%) | 2 (10) | 0 | 1 (6) | 3 (6) |
| Maintenance | ||||
| Patients with ≥1 maintenance cycle with IO, IG, or AG (%) | 19 (91) | 13 (100) | 16 (94) | 48 (94) |
| Mean no. of cycles | 6.9 | 4.9 | 3.7 | 5.3 |
| Patients with full 8 maintenance cycles, 24 mo (%) | 13 (68) | 6 (46) | 2 (13) | 21 (44) |
| Early discontinuation of maintenance (%) | ||||
| Due to adverse events | 1 (5) | 1 (8) | 0 | 2 (4) |
| Due to progressive disease | 4 (21) | 1 (8) | 2 (13) | 7 (15) |
| Death | 1 (5) | 0 | 0 | 1 (2) |
| Discontinuation of maintenance due to uMRD (%) | 0 | 5 (39) | 12 (75) | 17 (35) |
| Mean no. (range) of cycles | NA | 2.4 (2-4) | 3.3 (2-6) | 3.0 (2-6) |
| Duration of treatment | ||||
| Mean (range) duration, mo, of | ||||
| All treatment: debulking, induction, maintenance | 25 (5-32) | 23 (13-34) | 18 (4-30) | 22 (4-34) |
| Targeted treatment: induction and maintenance | 24 (5-31) | 22 (12-32) | 17 (4-30) | 21 (4-32) |